Group 1 - The core viewpoint of the article highlights the performance of the Ping An CSI A50 ETF, which reported a net value growth rate of 16.91% over the past year [1] - The fund's top ten holdings saw the addition of Luxshare Precision, while Citic Securities exited the top ten [1] - The largest holding in the fund is CATL, accounting for 11.08% of the total holdings, with a significant reduction in positions for several other stocks [1] Group 2 - The report provides detailed changes in the fund's top holdings, including a 22.68% reduction in CATL shares, a 22.5% reduction in Kweichow Moutai, and a 22.55% reduction in Ping An Insurance [1] - Luxshare Precision was newly added to the top ten holdings with 3.21 million shares valued at 208 million yuan [1] - The fund's recent performance includes a 0.96% change over the last five days, with a net inflow of 14.639 million yuan [3]

Core Viewpoint - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the launch of HR20031 tablets, which are indicated for improving blood sugar control in adults with type 2 diabetes who have inadequate control with metformin [1] Company Summary - Heng Rui Medicine (600276) announced the approval of its HR20031 tablets, which combine empagliflozin, linagliptin, and metformin [1] - The approved indication for HR20031 is to be used in conjunction with diet control and exercise for adult patients with type 2 diabetes [1] Industry Summary - The approval of HR20031 tablets reflects ongoing advancements in diabetes treatment options within the pharmaceutical industry [1] - The product aims to address the needs of patients with type 2 diabetes who struggle with blood sugar control despite existing treatments [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for its innovative oral diabetes medication, marking a significant advancement in the treatment of type 2 diabetes in China [1] Group 1: Product Information - The approved product is named Henggeli Jing Ruige Liting Metformin Sustained-Release Tablets (I) and (II) [1] - It is the first self-developed fixed-dose combination of three oral hypoglycemic agents in China [1] - The product is classified as a chemical drug of category 2.3, with specifications of 5/50/750 mg and 10/100/1000 mg [1] Group 2: Indications and Usage - The approved indication for the product is to improve blood sugar control in adult patients with type 2 diabetes who have inadequate blood sugar control with metformin hydrochloride, in conjunction with diet and exercise [1] - It is categorized as a prescription drug [1]

Group 1 - Company announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the launch of HR20031 tablets, which is China's first self-developed oral hypoglycemic combination fixed-dose formulation [1] - HR20031 tablets consist of three active ingredients: Prandial Glucose Regulators, Regaglitin, and Metformin, and are intended for adult patients with type 2 diabetes who have inadequate blood sugar control after Metformin treatment [2] - The product aims to simplify the treatment regimen by reducing the number of medications taken, thereby improving patient adherence to therapy [2] Group 2 - Diabetes has become the third most serious chronic disease affecting human health, with a prevalence rate of 13.79% among adults in China, translating to approximately 148 million patients [2] - The blood sugar control rate among type 2 diabetes patients is only 50.1%, indicating a significant need for effective treatment options [2] - The total research and development investment for HR20031 tablets has reached approximately 189.24 million yuan [2]

Company Summary - Heng Rui Medicine has received approval from the National Medical Products Administration for its HR20031 tablet, which is the first self-developed oral hypoglycemic combination drug in China [1] - The HR20031 tablet combines three active ingredients: empagliflozin, regaglitazone, and metformin, aimed at improving blood sugar control in adults with type 2 diabetes who have inadequate control with metformin alone [2] - The total R&D investment for the HR20031 project has reached approximately 189.24 million yuan [2] Industry Summary - Diabetes has become the third most serious chronic disease affecting human health, following cancer and cardiovascular diseases [2] - According to the International Diabetes Federation, the diabetes prevalence rate among Chinese adults (ages 20-79) is 13.79%, with approximately 148 million patients, making China the country with the highest number of diabetes patients [2] - The clinical medication adherence for type 2 diabetes patients is poor, with only 50.1% achieving adequate blood sugar control [2] - The HR20031 tablet aims to simplify the treatment regimen by reducing the number of medications needed, thereby improving patient adherence [2] - Currently, there are no similar combination drugs approved for sale in China, while a comparable product, TRIJARDY XR, is available internationally [2]

Core Viewpoint - The announcement highlights that the company has received approval for its innovative oral diabetes medication, marking a significant milestone in the pharmaceutical industry in China [1] Group 1 - The company, Shandong Shengdi Pharmaceutical Co., Ltd., a subsidiary of Heng Rui Medicine, has received notification from the National Medical Products Administration [1] - The approved product is Henggeli Jining Regaglitin Metformin Sustained-Release Tablets (HR20031), which is the first self-developed oral hypoglycemic combination drug in China [1] - This product represents a significant advancement in diabetes treatment options available in the Chinese market [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the launch of its oral hypoglycemic drug, HR20031, which is the first self-developed fixed-dose combination of three oral hypoglycemic agents in China [1] Company Summary - The approved product, HR20031, is a combination of empagliflozin, linagliptin, and metformin extended-release tablets [1] - It is indicated for adult patients with type 2 diabetes who have inadequate blood sugar control with metformin hydrochloride, in conjunction with diet and exercise [1] - This marks a significant milestone as there are currently no similar products approved for sale in the domestic market [1]

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-165 批准的适应症：本品配合饮食控制和运动，用于经盐酸二甲双胍治疗血糖控 制不佳的成人 2 型糖尿病患者改善血糖控制。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司山东盛迪医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）的通知，批准 公司恒格列净瑞格列汀二甲双胍缓释片（Ⅰ）、（Ⅱ）（HR20031 片）上市，该 产品是中国首个自主研发的口服降糖三药联合固定复方制剂，现将相关情况公告 如下： 一、药品的基本情况 药品名称：恒格列净瑞格列汀二甲双胍缓释片（Ⅰ）、（Ⅱ） 剂型：片剂 规格：5/50/750mg、10/100/1000mg 注册分类：化学药品 2.3 类 受理号：CXHS2300099、CXHS2300100 处方药/非处方药：处方药 江苏恒瑞医药股份有限公司 关于获得药品注册批准的公告 [1]. IDF Diabetes Atlas 11th edition. https:/ ...

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for its subsidiary Shandong Shengdi Medicine to launch HR20031 tablets, a fixed-dose combination of three oral hypoglycemic agents, marking a significant advancement in diabetes treatment in China [1] Product Details - HR20031 tablets are the first self-developed oral hypoglycemic combination product in China, available in specifications of 5/50/750mg and 10/100/1000mg [1] - The product is classified as a chemical drug category 2.3 and is a prescription medication [1] - It is indicated for adults with type 2 diabetes who have inadequate blood sugar control despite treatment with metformin, in conjunction with diet and exercise [1] Mechanism and Market Position - The product utilizes three different mechanisms to lower blood sugar, simplifying the medication regimen and potentially improving patient adherence [1] - There are currently no similar products approved in China, while the international equivalent is TRIJARDY XR [1] R&D Investment - The cumulative research and development investment for HR20031 tablets has reached approximately 189.24 million yuan [1] Production and Sales Uncertainty - The company has indicated that there are uncertainties associated with the production and sales of the drug, advising investors to be cautious [1]

Core Insights - The announcement highlights that the subsidiary Shandong Shengdi Pharmaceutical has received approval from the National Medical Products Administration for the launch of a new oral diabetes medication, HR20031, which is the first self-developed fixed-dose combination of three antidiabetic drugs in China [1] Company Summary - The approved product, HR20031, is a combination of empagliflozin, linagliptin, and metformin, aimed at improving blood sugar control in adult patients with type 2 diabetes who have inadequate glycemic control with metformin alone [1] - The product is available in two specifications: 5/50/750 mg and 10/100/1000 mg [1] - The total research and development investment for this product has reached approximately 189 million yuan [1] Industry Summary - Currently, there are no similar products approved for market in China, indicating a unique position for the company in the diabetes treatment market [1]